Two Star Manager LLC Purchases 7,693 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Two Star Manager LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 63.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 19,793 shares of the medical research company’s stock after acquiring an additional 7,693 shares during the period. Thermo Fisher Scientific accounts for 4.8% of Two Star Manager LLC’s holdings, making the stock its 11th biggest position. Two Star Manager LLC’s holdings in Thermo Fisher Scientific were worth $10,297,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in Thermo Fisher Scientific by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company’s stock worth $17,297,426,000 after purchasing an additional 196,864 shares during the period. Capital World Investors boosted its holdings in Thermo Fisher Scientific by 1.1% in the 4th quarter. Capital World Investors now owns 9,430,120 shares of the medical research company’s stock worth $4,905,812,000 after buying an additional 104,343 shares during the last quarter. Geode Capital Management LLC lifted its stake in Thermo Fisher Scientific by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company’s stock worth $4,075,540,000 after purchasing an additional 197,442 shares in the last quarter. Norges Bank purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $3,149,754,000. Finally, Northern Trust Corp lifted its stake in Thermo Fisher Scientific by 13.2% in the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company’s stock worth $2,034,107,000 after purchasing an additional 455,004 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of several analyst reports. Evercore ISI reduced their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Barclays dropped their target price on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Raymond James reiterated an “outperform” rating and issued a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a report on Thursday, April 24th. Finally, UBS Group dropped their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research note on Thursday, April 24th. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $607.43.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $412.15 on Friday. The firm has a market cap of $155.58 billion, a P/E ratio of 24.93, a P/E/G ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 1-year low of $390.50 and a 1-year high of $627.88. The firm has a fifty day moving average of $453.88 and a two-hundred day moving average of $510.15.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same period last year, the business earned $5.11 EPS. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.42%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.09%.

Insiders Place Their Bets

In other news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares of the company’s stock, valued at $5,759,736.32. The trade was a 25.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,075 shares of company stock worth $7,305,942. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.